Your search returned 11 results.

Results
	1.	Sevoflurane formulation water content influences degradation by Lewis acids in vaporizers. [electronic resource] by Kharasch, Evan D Subbarao, Gowdahalli N Cromack, Keith R Stephens, Dennis A Saltarelli, Mario D Producer: 20090605 In: Anesthesia and analgesia vol. 108 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	2.	Divalproex sodium in children with partial seizures: 12-month safety study. [electronic resource] by Lenz, Robert A Elterman, Roy D Robieson, Weining Z Vigna, Namita V Saltarelli, Mario D Producer: 20090921 In: Pediatric neurology vol. 41 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	3.	A randomized, double-blind, placebo-controlled phase 2 study of α4β2 agonist ABT-894 in adults with ADHD. [electronic resource] by Bain, Earle E Robieson, Weining Pritchett, Yili Garimella, Tushar Abi-Saab, Walid Apostol, George McGough, James J Saltarelli, Mario D Producer: 20131017 In: Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology vol. 38 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	4.	Divalproex sodium extended-release for the prophylaxis of migraine headache in adolescents: results of a stand-alone, long-term open-label safety study. [electronic resource] by Apostol, George Lewis, Donald W Laforet, Genevieve A Robieson, Weining Z Fugate, Julie M Abi-Saab, Walid M Saltarelli, Mario D Producer: 20090430 In: Headache vol. 49 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	5.	A randomized pilot study of the efficacy and safety of ABT-089, a novel α4β2 neuronal nicotinic receptor agonist, in adults with attention-deficit/hyperactivity disorder. [electronic resource] by Bain, Earle E Apostol, George Sangal, R Bart Robieson, Weining Z McNeill, Dawnelle L Abi-Saab, Walid M Saltarelli, Mario D Producer: 20120926 In: The Journal of clinical psychiatry vol. 73 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	6.	The scopolamine model as a pharmacodynamic marker in early drug development. [electronic resource] by Lenz, Robert A Baker, Jeffrey D Locke, Charles Rueter, Lynne E Mohler, Eric G Wesnes, Keith Abi-Saab, Walid Saltarelli, Mario D Producer: 20120604 In: Psychopharmacology vol. 220 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	7.	Blockade of [11C](+)-PHNO binding in human subjects by the dopamine D3 receptor antagonist ABT-925. [electronic resource] by Graff-Guerrero, Ariel Redden, Laura Abi-Saab, Walid Katz, David A Houle, Sylvain Barsoum, Penny Bhathena, Anahita Palaparthy, Ramesh Saltarelli, Mario D Kapur, Shitij Producer: 20100624 In: The international journal of neuropsychopharmacology vol. 13 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	8.	A double-blind, randomized, placebo-controlled study of the dopamine D₃ receptor antagonist ABT-925 in patients with acute schizophrenia. [electronic resource] by Redden, Laura Rendenbach-Mueller, Beatrice Abi-Saab, Walid M Katz, David A Goenjian, Armen Robieson, Weining Z Wang, Yaqin Goss, Sandra L Greco, Nicholas Saltarelli, Mario D Producer: 20111221 In: Journal of clinical psychopharmacology vol. 31 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	9.	Adaptive, dose-finding phase 2 trial evaluating the safety and efficacy of ABT-089 in mild to moderate Alzheimer disease. [electronic resource] by Lenz, Robert A Pritchett, Yili L Berry, Scott M Llano, Daniel A Han, Shu Berry, Donald A Sadowsky, Carl H Abi-Saab, Walid M Saltarelli, Mario D Producer: 20160802 In: Alzheimer disease and associated disorders vol. 29 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	10.	Efficacy and safety of the novel α₄β₂ neuronal nicotinic receptor partial agonist ABT-089 in adults with attention-deficit/hyperactivity disorder: a randomized, double-blind, placebo-controlled crossover study. [electronic resource] by Apostol, George Abi-Saab, Walid Kratochvil, Christopher J Adler, Lenard A Robieson, Weining Z Gault, Laura M Pritchett, Yili L Feifel, David Collins, Michelle A Saltarelli, Mario D Producer: 20120924 In: Psychopharmacology vol. 219 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	11.	Safety and efficacy of ABT-089 in pediatric attention-deficit/hyperactivity disorder: results from two randomized placebo-controlled clinical trials. [electronic resource] by Wilens, Timothy E Gault, Laura M Childress, Ann Kratochvil, Christopher J Bensman, Lindsey Hall, Coleen M Olson, Evelyn Robieson, Weining Z Garimella, Tushar S Abi-Saab, Walid M Apostol, George Saltarelli, Mario D Producer: 20110419 In: Journal of the American Academy of Child and Adolescent Psychiatry vol. 50 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)